# Harmony Biosciences Record WAKIX Revenue Drives 10% Stock Surge

> news · REPORTED · 2026-07-22

Harmony Biosciences shares surged 10% on July 22, 2026, following the company's announcement of preliminary Q2 2026 WAKIX revenue of approximately $261 million, representing 30% year-over-year growth, backed by reaffirmed full-year guidance of $1.0 to $1.04 billion. The result reinforces the WAKIX franchise as the anchor of Harmony's rare-neurological-disease commercial strategy.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a Nasdaq-listed pharmaceutical company (HRMY) commercializing WAKIX (pitolisant) for narcolepsy and other rare neurological diseases, with a pipeline targeting additional sleep and CNS disorders.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://ca.finance.yahoo.com/news/harmony-biosciences-hrmy-soars-10-115800312.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.